Pesquisar
Dynavax Technologies Corp
DVAXAdicionar à lista de desejos
15.500USD
0.0000.00%
Fechamento 05/15, 16:00（ET）Cotações atrasadas em 15 min
1.76BValor de mercado
PerdaP/L TTM
Mais detalhes de Dynavax Technologies Corp Empresa
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Informações de Dynavax Technologies Corp
Código da empresaDVAX
Nome da EmpresaDynavax Technologies Corp
Data de listagemFeb 19, 2004
CEOSpencer (Ryan)
Número de funcionários405
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 19
Endereço2100 Powell Street
CidadeEMERYVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94608
Telefone15108485100
Sitehttps://www.dynavax.com/
Código da empresaDVAX
Data de listagemFeb 19, 2004
CEOSpencer (Ryan)
Executivos da empresa Dynavax Technologies Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
63.47K
+50.50%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
56.49K
+54.83%
Mr. David F. Novack
Mr. David F. Novack
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
46.64K
-135.79%
Dr. Peter R. Paradiso, Ph.D.
Dr. Peter R. Paradiso, Ph.D.
Independent Director
Independent Director
24.83K
+23.19%
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
16.47K
-2305.20%
Dr. Emilio Emini
Dr. Emilio Emini
Independent Director
Independent Director
1.44K
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
1.44K
--
Dr. Francis R. Cano, Ph.D.
Dr. Francis R. Cano, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel L. (Dan) Kisner, M.D.
Dr. Daniel L. (Dan) Kisner, M.D.
Independent Director
Independent Director
--
-100.00%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
63.47K
+50.50%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
56.49K
+54.83%
Mr. David F. Novack
Mr. David F. Novack
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
46.64K
-135.79%
Dr. Peter R. Paradiso, Ph.D.
Dr. Peter R. Paradiso, Ph.D.
Independent Director
Independent Director
24.83K
+23.19%
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
16.47K
-2305.20%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
HEPLISAV-B
89.95M
94.81%
Other revenue
4.92M
5.19%
Por RegiãoUSD
Nome
Receita
Proporção
US
94.69M
99.81%
Non-US
183.00K
0.19%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
HEPLISAV-B
89.95M
94.81%
Other revenue
4.92M
5.19%
Distribuição de ações
Atualizado em: qui, 14 de mai
Atualizado em: qui, 14 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
13.02%
State Street Investment Management (US)
6.30%
Renaissance Technologies LLC
2.94%
Two Sigma Investments, LP
2.61%
Marshall Wace LLP
2.21%
Outro
72.93%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
13.02%
State Street Investment Management (US)
6.30%
Renaissance Technologies LLC
2.94%
Two Sigma Investments, LP
2.61%
Marshall Wace LLP
2.21%
Outro
72.93%
Tipos de investidores
Investidores
Proporção
Investment Advisor
22.95%
Investment Advisor/Hedge Fund
20.56%
Hedge Fund
16.17%
Research Firm
4.45%
Pension Fund
0.49%
Individual Investor
0.31%
Bank and Trust
0.24%
Private Equity
0.04%
Venture Capital
0.02%
Outro
34.77%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
569
82.18M
72.29%
-46.77M
2025Q4
546
115.83M
109.38%
+66.95K
2025Q3
565
115.78M
113.44%
+813.17K
2025Q2
563
116.95M
120.36%
-13.51M
2025Q1
558
131.20M
118.77%
-16.39M
2024Q4
550
133.28M
116.08%
-4.50M
2024Q3
545
132.56M
115.53%
-2.40M
2024Q2
531
134.71M
114.10%
-1.03M
2024Q1
527
135.87M
107.19%
-4.14M
2023Q4
514
128.04M
106.45%
-253.89K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
14.80M
13.02%
+100.11K
+0.68%
Dec 31, 2025
State Street Investment Management (US)
7.16M
6.3%
+878.69K
+13.98%
Dec 31, 2025
Renaissance Technologies LLC
3.34M
2.94%
+198.99K
+6.34%
Dec 31, 2025
Two Sigma Investments, LP
2.97M
2.61%
-45.65K
-1.52%
Dec 31, 2025
Marshall Wace LLP
2.51M
2.21%
+473.77K
+23.27%
Dec 31, 2025
Geode Capital Management, L.L.C.
2.42M
2.12%
-115.34K
-4.56%
Dec 31, 2025
Soros Fund Management, L.L.C.
1.57M
1.38%
+1.57M
--
Dec 31, 2025
Sand Grove Capital Management LLP
1.53M
1.34%
+1.53M
--
Dec 31, 2025
Kynam Capital Management LP
1.38M
1.21%
-769.69K
-35.88%
Dec 31, 2025
Goldman Sachs & Company, Inc.
1.26M
1.11%
+248.48K
+24.57%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Invesco Biotechnology & Genome ETF
2.91%
Virtus LifeSci Biotech Products ETF
1.58%
ETC 6 Meridian Small Cap Equity ETF
1.21%
Invesco S&P SmallCap Health Care ETF
0.62%
ETC 6 Meridian Low Beta Equity Strategy ETF
0.46%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.42%
State Street SPDR S&P Biotech ETF
0.41%
Themes US Small Cap Cash Flow Champions ETF
0.35%
Royce Quant Small-Cap Quality Value ETF
0.29%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
Ver Mais
Invesco Biotechnology & Genome ETF
Proporção2.91%
Virtus LifeSci Biotech Products ETF
Proporção1.58%
ETC 6 Meridian Small Cap Equity ETF
Proporção1.21%
Invesco S&P SmallCap Health Care ETF
Proporção0.62%
ETC 6 Meridian Low Beta Equity Strategy ETF
Proporção0.46%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporção0.42%
State Street SPDR S&P Biotech ETF
Proporção0.41%
Themes US Small Cap Cash Flow Champions ETF
Proporção0.35%
Royce Quant Small-Cap Quality Value ETF
Proporção0.29%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.25%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
